AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 32 min read$ALECNeutralLow

Rosenthal Arnon sold $172K of ALEC

Rosenthal Arnon (Chief Executive Officer) sold 87,216 shares of Alector, Inc. (ALEC) at $1.97 ($0.17M total) on 2026-06-02.

Rosenthal ArnonJune 3, 2026
AI analysis
Relevance
6/10
Novelty
6/10
Actionability
Low
Sentiment · $ALEC
Neutral
Timing
Filed after-hours/late day (2026-06-03), reflecting sale executed 2026-06-02.
Market alignment
Neutral-to-slightly negative (insider selling), but not a clear directional signal without additional context.
Why this matters for $ALEC

Insider selling is a near-term sentiment datapoint, but this single Form 4 (no 10b5-1) is not itself a fundamental catalyst.

Relevance context

Alector CEO Rosenthal Arnon sold 87,216 shares in an open-market transaction, disclosing direct insider selling at $1.9743/share.

Price-impact prediction

Likely limited, with any effect more sentiment-driven than trend-changing unless follow-on selling continues.

Background

The article is an SEC Form 4 insider transaction disclosure for Alector, Inc. (ALEC).

Why it matters

This provides a concrete insider selling datapoint (shares, price, and remaining holdings) but no new operational or clinical information.

Market relevance

Traders may monitor ALEC for sentiment drift or continued insider selling, but the filing alone is unlikely to drive a major repricing.

Market effects

Sector

Minimal sector read-through; this is company-specific insider activity without broader industry news.

Regional

None indicated.

Global

None indicated.

Alternative perspectives

Contrarian view

The sale could be routine liquidity/portfolio management rather than a bearish signal, especially given the large remaining holdings.

Overlooked factors

No 10b5-1 plan is stated, but Form 4s alone don’t reveal intent; traders may need follow-on filings, volume/price reaction, and any concurrent corporate catalysts.

Key entities

  • issuer
    Alector, Inc.

    Subject of the SEC Form 4 insider sale by the CEO.

  • insider
    Rosenthal Arnon

    CEO/Officer/Director who sold 87,216 shares in an open-market transaction.

Read at source← All news

Related articles

JUN 8
$ALECMedAI 8/10

UAE Business: ALEC unit Target wins $500m three EPC contracts in Gulf

ALEC Holdings said its subsidiary Target Engineering Construction Company – SP won three Gulf EPC contracts totaling over $500 million, according to a filing to the Dubai Stock Market. The projects have execution periods of 10, 21 and 36 months. ALEC said the awards’ financial impact will be recognized over those periods under its revenue policy, and it did not name clients, locations or scope.

gdnonline.com3 min
MAY 7
$ALECLow

Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus

Alector (NASDAQ: ALEC) reported its Q1 2026 financial results, revealing a narrowed net loss of $22.9 million and a strategic pivot towards its Alector Brain Carrier (ABC) platform. This shift follows the discontinuation of its Phase 2 Alzheimer's trial for nivisnebart due to a futility analysis. The company maintains a cash runway expected to fund operations through at least 2027, focusing on advancing multiple preclinical ABC-enabled programs for neurodegenerative diseases.

Stock Titan4 min
MAR 14
$ALECMed

Alector (ALEC) CEO awarded 116,246 RSUs, boosts direct share stake

Alector, Inc. CEO Arnon Rosenthal was granted 116,246 restricted stock units (RSUs) on March 13, 2026, as equity compensation. These RSUs, which have no cash cost, will vest in two equal installments on September 1, 2026, and March 1, 2027. This grant increases his direct ownership to 2,454,422 common shares, in addition to indirect holdings through family trusts.

Stock Titan2 min
DEC 12
$ALECMed

Alector (ALEC) Appoints Neil Berkley as CFO

Alector (ALEC) has appointed Neil Berkley as Chief Financial Officer, effective December 10, 2025, while he will also retain his responsibilities as Chief Business Officer. The biotechnology company, which focuses on neurodegenerative therapies, faces significant financial challenges including negative margins and declining revenue growth. Despite a stable liquidity position, an Altman Z-Score of -3.61 indicates potential bankruptcy risk, and recent insider activity shows substantial selling with no buying.

GuruFocus3 min